Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT
详细信息 查看全文
- 作者：Giuseppe Lippi (1) glippi@ao.pr.it
Emmanuel J. Favaloro (2)
Massimo Franchini (3) - 关键词：Thrombosis – ; Atypical – ; Paradoxical – ; Pathogenesis – ; Haemophilia – ; Von Willebrand disease
- 刊名：Journal of Thrombosis and Thrombolysis
- 出版年：2012
- 出版时间：October 2012
- 年：2012
- 卷：34
- 期：3
- 页码：360-366
- 全文大小：213.6 KB
- 参考文献：1. Lippi G, Franchini M, Targher G (2011) Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol 8:502–512
2. Lijfering WM, Flinterman LE, Vandenbroucke JP, Rosendaal FR, Cannegieter SC (2011) Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Semin Thromb Hemost 37:885–896
3. Lippi G, Franchini M (2008) Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost 34:747–761
4. Lippi G, Franchini M, Favaloro EJ (2009) Unsuspected triggers of venous thromboembolism—trivial or not so trivial? Semin Thromb Hemost 35:597–604
5. Montagnana M, Favaloro EJ, Franchini M, Guidi GC, Lippi G (2010) The role of ethnicity, age and gender in venous thromboembolism. J Thromb Thrombolysis 29:489–496
6. Lippi G, Favaloro EJ, Franchini M (2011) Coagulopathies and thrombosis: usual and unusual causes and associations, Part IV. Semin Thromb Hemost 37:175–180
7. Favaloro EJ, Franchini M, Lippi G (2011) Coagulopathies and thrombosis: usual and unusual causes and associations Part V. Semin Thromb Hemost 37:859–862
8. The free dictionary. Definition of paradoxical. Available at: http://www.thefreedictionary.com/paradoxical
9. Lehmeyer S, Lindhoff-Last E (2011) New aspects of paradoxical embolism. Vasa 40:31–40
10. Makris M, Colvin B, Gupta V, Shields ML, Smith MP (2002) Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand’s disease. Thromb Haemost 88:387–388
11. Franchini M (2004) Thrombotic complications in patient with hereditary bleeding disorders. Thromb Haemost 92:298–304
12. Franchini M (2008) Surgical prophylaxis in von Willebrand’s disease: a difficult balance to manage. Blood Transfus 6(Suppl. 2):S33–S38
13. Mannucci PM, Chediak J, Hanna W, Byrnes J, Marlies L, Ewenstein BM, and the Alphanate Study Group (2002) Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 99:450–456
14. Franchini M, Rossetti G, Tagliaferri A et al (2003) Efficacy and safety of factor VIII/von Willebrand factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand’s disease. Haematologica 88:1279–1283
15. Iorio A, Matino D, D’Amico R, Makris M (2010) Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev (8): CD004449
16. Franchini M, Tagliaferri A, Rossetti G et al (2004) Absence of thromboembolic complications in patients with hereditary bleeding disorders undergoing major orthopedic surgery without antithrombotic prophylaxis. Thromb Haemost 91:1053–1055
17. Kopitsky RG, Geltman EM (1985) Unstable angina associated with factor VIII concentrate therapy for hemophilia A. Ann Intern Med 105:215–216
18. Ritchie B, Woodman RC, Poon MC (1992) Deep venous thrombosis in hemophilia A. Am J Med 93:699–700
19. Djulbegovic B (1995) Lack of prophylactic anticoagulant therapy is not associated with clinical thrombotic complications in patients with hemophilia who undergo orthopedic surgical procedures. Am J Hematol 50:229–230
20. Lowe GDO (2001) Factor IX and thrombosis. Br J Haematol 115:507–513
21. Lusher JM (1991) Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 28:3–5
22. Santagostino E, Mannucci PM, Gringeri A et al (1994) Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery. Thromb Haemost 71:737–740
23. Franchini M, Targher G, Montagnana M, Lippi G (2009) Antithrombotic prophylaxis in patients with von Willebrand disease undergoing major surgery: when is it necessary? J Thromb Thrombolysis 28:215–219
24. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345:152–155
25. Kraaijenhagen RA, Anker PS, Koopman MMW et al (2000) High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 83:5–9
26. Mannucci PM (2002) Venous thromboembolism in von Willebrand disease. Thromb Haemost 88:378–379
27. Mannucci PM, Chediak J, Hanna W, Byrnes J, Marlies L, Ewenstein BM, and the Alphanate Study Group (2002) Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 99:450–456
28. Coppola A, Franchini M, Makris M, Santagostino E, DI Minno G, Mannucci PM (2012) Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia. 2012 Feb 15. [Epub ahead of print]
29. Lippi G, Franchini M, Montagnana M, Favaloro EJ (2011) Inherited disorders of blood coagulation. Ann Med. 2011 May 17. [Epub ahead of print]
30. Girolami A, Ruzzon E, Tezza F, Scandellari R, Vettore S, Girolami B (2006) Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review. Haemophilia 12:345–351
31. Woodruff RS, Sullenger B, Becker RC (2011) The many faces of the contact pathway and their role in thrombosis. J Thromb Thrombolysis 32:9–20
32. Stavrou E, Schmaier AH (2010) Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thromb Res 125:210–215
33. Ratnoff OD, Colopy JE (1955) Familial hemorrhagic trait associated with deficiency of clot-promoting fraction of plasma. J Clin Invest 34:602–613
34. Lippi G, Franchini M, Brazzarola P, Manzato F (2001) Preoperative screening: the rationale of measuring APTT in risk assessment. Haematologica 86:328
35. Halbmayer WM, Mannhalter C, Feichtinger C, Rubi K, Fischer M (1993) Factor XII (Hageman factor) deficiency: a risk factor for development of thromboembolism. Incidence of factor XII deficiency in patients after recurrent venous or arterial thromboembolism and myocardial infarction. Wien Med Wochenschr 143:43–50
36. Girolami A, Randi ML, Gavasso S, Lombardi AM, Spiezia F (2004) The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature. J Thromb Thrombolysis 17:139–143
37. Doggen CJ, Rosendaal FR, Meijers JC (2006) Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood 108:4045–4051
38. Gallimore MJ, Harris SL, Jones DW, Winter M (2004) Plasma levels of factor XII, prekallikrein and high molecular weight kininogen in normal blood donors and patients having suffered venous thrombosis. Thromb Res 114:91–96
39. Endler G, Marsik C, Jilma B, Schickbauer T, Quehenberger P, Mannhalter C (2007) Evidence of a U-shaped association between factor XII activity and overall survival. J Thromb Haemost 5:1143–1148
40. Johnson CY, Tuite A, Morange PE, Tregouet DA, Gagnon F (2011) The factor XII -4C > T variant and risk of common thrombotic disorders: a HuGE review and meta-analysis of evidence from observational studies. Am J Epidemiol 173:136–144
41. Lessiani G, Falco A, Nicolucci E, Rolandi G, Dav矛 G (2009) Deep venous thrombosis and previous myocardial infarction in mild factor XII deficiency: a risk factor for both venous and arterial thrombosis. J Thromb Thrombolysis 27:348–351
42. de Moerloose P, Neerman-Arbez M (2009) Congenital fibrinogen disorders. Semin Thromb Hemost 35:356–366
43. de Moerloose P, Boehlen F, Neerman-Arbez M (2010) Fibrinogen and the risk of thrombosis. Semin Thromb Hemost 36:7–17
44. Castaman G, Lunardi M, Rigo L, Mastroeni V, Bonoldi E, Rodeghiero F (2009) Severe spontaneous arterial thrombotic manifestations in patients with inherited hypo- and afibrinogenemia. Haemophilia 15:533–537
45. Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci PM (1999) Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 107:204–206
46. Simsek I, de Mazancourt P, Horellou MH, Erdem H, Pay S, Dinc A, Samama MM (2008) Afibrinogenemia resulting from homozygous nonsense mutation in A alpha chain gene associated with multiple thrombotic episodes. Blood Coagul Fibrinolysis 19:247–253
47. Mariani G, Bernardi F (2009) Factor VII deficiency. Semin Thromb Hemost 35:400–406
48. Escoffre M, Zini JM, Schliamser L, Mazoyer E, Soria C, Tobelem G, Dupuy E (1995) Severe arterial thrombosis in a congenitally factor VII deficient patient. Br J Haematol 91:739–741
49. Mariani G, Herrmann FH, Schulman S, International Factor VII Deficiency Study Group et al (2003) Thrombosis in inherited factor VII deficiency. J Thromb Haemost 1:2153–2158
50. Marty S, Barro C, Chatelain B et al (2008) The paradoxical association between inherited factor VII deficiency and venous thrombosis. Haemophilia 14:564–770
51. Girolami A, Berti de Marinis G, Vettore S, Girolami B (2012) Congenital FVII deficiency and pulmonary embolism : a critical appraisal of all reported cases. Clin Appl Thromb Hemost. 2012 Feb 12. [Epub ahead of print]
52. Girolami A, Tezza F, Scandellari R, Vettore S, Girolami B (2010) Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. Critical review of the literature. J Thromb Thrombolysis 30:172–178
53. Miyakis S, lockshin MD, Atsumi I et al (2006) International concensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306
54. Favaloro EJ, Wong RCW (2010) The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours? Autoimmun Highlights 1:5–14
55. Favaloro EJ, Wong R (2011) Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. Clin Chem Lab Med 49:447–461
56. Heilmann L, Schorsch M, Hahn T, Fareed J (2011) Antiphospholipid syndrome and pre-eclampsia. Semin Thromb Hemost 37:141–145
57. Galli M, Luciani D, Bertolini G, Barbui T (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101:1827–1832
58. Kenet G, Aronis S, Berkun Y et al (2011) Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. Semin Thromb Hemost 37:802–809
59. Pengo V, Manzato A, Bison E, Bracco A, Denas G, Ruffatti A (2012) What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? Semin Thromb Hemost. doi:
60. Galli M (2012) Interpretation and recommended testing for antiphospholipid antibodies. Semin Thromb Hemost. doi:
61. Franchini M, Lippi G, Favaloro EJ (2012) Acquired inhibitors of coagulation factors: Part II. Semin Thromb Hemost. doi:10.1055/s-0032-1305779
62. Mehdi AA, Salti I, Uthman I (2011) Antiphospholipid syndrome: endocrinologic manifestations and organ involvement. Semin Thromb Hemost 37:49–57
63. Cervera R, Espinosa G (2012) Update on the catastrophic antiphospholipid syndrome and the “CAPS registry”. Semin Thromb Hemost. doi:
64. Les I, Ruiz-Irastorza G, Khamashta MA (2012) Intensity and duration of anticoagulation therapy in the Antiphospholipid Syndrome. Semin Thromb Hemost. doi: - 作者单位：1. U.O di Diagnostica Ematochimica, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero-Universitaria di Parma, Via Gramsci 14, 43126 Parma, Italy2. Servizio di Immunoematologia e Trasfusione, Ospedale Carlo Poma, Mantua, Italy3. Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, Australia
- ISSN：1573-742X
文摘
The pathogenesis of venous and arterial thrombosis is complex and multifaceted, entailing a multitude of risk factors, which only marginally overlap between the two vessels districts. Along with conventional and universally recognized risk factors, thrombosis might also develop as a consequence of unusual, atypical, unsuspected and even paradoxical conditions. Although the term “paradoxical embolism” is typically used to identify an embolization process that originates from the low-pressure venous system and may generate ischemic stroke or peripheral arterial occlusion through a cardiac or pulmonary shunt, there are additional clinical circumstances whereby the risk of thrombosis is surprising, unpredicted or even neglected. In this article we thereby analyze the prevalence, as well as the pathogenesis, of thrombosis associated with apparently paradoxical triggers such as during factor replacement therapy in haemophiliacs or in patients with von Willebrand disease; in patients with inherited clotting factor deficiencies especially involving factor XII, factor VII, fibrinogen; or in those with a prolonged activated partial thromboplastin time for the presence of lupus anticoagulant.